ASA in Prevention of Ovarian Cancer (STICs and STONEs)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

July 24, 2018

Primary Completion Date

December 15, 2025

Study Completion Date

September 15, 2026

Conditions
Ovarian Cancer Prevention
Interventions
DRUG

Acetylsalicylic acid

81 mg PO daily or 325 mg PO daily

OTHER

Placebo

One tablet PO daily

Trial Locations (17)

2031

Prince of Wales Hospital, Randwick

2050

Royal Prince Alfred Hospital, Camperdown

2145

Westmead Hospital, Westmead

3002

Peter McCallum Cancer Institute, Melbourne

6008

King Edward Memorial Hospital, Subiaco

St John of God Subiaco, Subiaco

T2N 4N2

Tom Baker Cancer Centre, Calgary

V5Z 1M9

Clinical Research Unit at Vancouver Coastal, Vancouver

R3E 0V9

CancerCare Manitoba, Winnipeg

A1B 3V6

Dr. H. Bliss Murphy Cancer Centre, St. John's

K7L 2V7

Kingston Health Sciences Centre, Kingston

M2K 1E1

North York General Hospital, Toronto

M5S 1B2

Women's College Hospital, Toronto

H1T 2M4

CIUSSS de l'Est-de-I'lle-de-Montreal, Montreal

H2X 3E4

CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal

G1R 2J6

Hotel-Dieu de Quebec, Québec

J1H 5N4

CIUSSS de l'Estrie - Centre hospitalier, Sherbrooke

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Apotex Inc.

INDUSTRY

lead

Canadian Cancer Trials Group

NETWORK